Up to 80% of MEN1 patients develop primary hyperparathyroidism associated with parathyroid adenomas and with a female predominance [89], while up to 25% develop pituitary adenomas (prolactinomas, growth hormone, rare TSH, ACTH, nonfunctioning). This evidence concerns the gene POMC and pituitary gland adenoma.